“Androgen-deprivation therapy, while an effective treatment for prostate cancer, can result in side effects and a reduced quality of life. Allowing low-risk patients to take breaks between treatments—a practice known as intermittent hormonal therapy, or a ‘hormone holiday’—may combat these challenges without impacting survival.
“A recent systematic review and meta-analysis conducted by JAMA Oncology found no significant difference between intermittent and continuous therapy for overall survival (HR, 1.02; 95% CI, 0.93-1.11; 8 trials, 5352 patients), cancer-specific survival (HR, 1.02; 95% CI, 0.87-1.19; 5 trials, 3613 patients), and progression-free survival (HR, 0.94; 95% CI, 0.84-1.05; 4 trials, 1774 patients).”
Zhu J, Zheng Y. Journal of Clinical Oncology. Sep 23, 2013.
“TO THE EDITOR: We read with interest the recent article by Niraula et al, in which the authors analyzed the results of published literature regarding intermittent versus continuous androgen deprivation in patients with prostate cancer. The authors concluded that intermittent androgen deprivation (IAD) should be used instead of continuous androgen deprivation (CAD) for the treatment of men with relapsing, locally advanced, or metastatic prostate cancer who achieve a good initial response to androgen deprivation. With the addition of a recently published study by Silva et al, there were ﬁve large randomized trials (>500 participants), directly comparing IAD with CAD therapy for advanced prostate cancer. However, three trials that included mixed populations (patients with locally advanced or metastatic prostate cancer) had some methodologic imperfections and bias that may inﬂuence the accuracy of outcomes.”